Back to top
more

ARK Genomic Revolution ETF: (ARKG)

(Real Time Quote from BATS) As of Nov 19, 2026 01:12 PM ET

$40.65 USD

40.65
2,360,397

-0.61 (-1.48%)

Volume: 2,360,397

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

Zacks News

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

Sanghamitra Saha headshot

4 Top Sectors of Last Week & Their Winning ETFs

These sectors topped last week and beat the broader market in a sweeping move.

Sweta Killa headshot

10 ETFs Up More Than 30% in a Month

The stabilization in the spread of the disease, hopes for re-opening of the economy anytime soon, and increased progress of drugmakers' to develop COVID-19 treatment has boosted confidence in the stock market.

Sanghamitra Saha headshot

Coronavirus Scare Supports These Biotech ETFs & Stocks

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Sweta Killa headshot

Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Zacks Equity Research

The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG

The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG